Peptide library

Copper peptides and hair:
what the studies measured

Searches for “copper peptides for hair” lead to scalp serums and hair-loss videos featuring GHK-Cu. Here is each hair study we found, its model and size, and where regulators draw the line between a cosmetic and a hair-loss drug.

Short answerCompound research · 6 min read · Updated 18 Nov 2026

The only placebo-controlled study of a GHK-Cu serum we found was in the eyebrows of 18 healthy adults, in conference proceedings. Other human hair studies used GHK without copper or mixed a copper peptide with other actives. We found no controlled trial of GHK-Cu alone for scalp hair loss. In the US, a claim that a product will restore hair growth makes it a drug.

Key takeaways

  • “Copper peptides” covers more than one molecule: GHK-Cu (copper tripeptide-1), AHK-Cu and a code-named research peptide; one hair trial used GHK without copper.
  • The only placebo-controlled study of a GHK-Cu serum we found was in the eyebrows of 18 healthy adults, published in conference proceedings in 2026.
  • Every other human study we found used GHK without copper, combined a copper peptide with other actives or drugs, or had no control group; we found no copper-peptide hair study on ClinicalTrials.gov.
  • In the US, a claim that a product will restore hair growth makes it a drug, and non-prescription hair growers need an approved application.
  • FDA-approved medicines for pattern hair loss include topical minoxidil and prescription finasteride; no GHK-Cu medicine appears in Drugs@FDA.

01Copper peptides and hair at a glance

Hair studies only, dated 18 November 2026. The compound’s wider research is on the GHK-Cu research guide, its skin studies on topical GHK-Cu, and peptides in creams and serums generally on peptides in skincare.

QuestionCopper peptides and hair
What “copper peptides” meansShort peptides bound to copper. The best known is GHK-Cu, the copper complex of glycyl-histidyl-lysine, listed in cosmetics as copper tripeptide-1. Hair research has also used AHK-Cu, a different copper tripeptide, and GHK without copper.
Human evidence for hairT1, small: one randomised eyebrow study of a GHK-Cu serum in 18 healthy adults, in conference proceedings. Other human studies, some of them large, tested formulations or procedures in which a copper peptide was one of several actives, so they cannot isolate its effect.
Animal and lab evidenceT3/T4: rats (1993), mice (1991, known to us only by its title), and human hair follicles kept alive in the lab (2007, AHK-Cu).
Registered studiesNone of a copper peptide for hair on ClinicalTrials.gov (searched 18 Nov 2026).
FDA-approved medicines for pattern hair lossThese include topical minoxidil (first approved 1988, now over the counter) and finasteride tablets (Propecia, approved 1997, prescription).
US ruleA claim that a product will restore hair growth makes it a drug. No GHK-Cu medicine appears in Drugs@FDA.
United KingdomUK law treats a product given to restore, correct or modify physiological functions through a pharmacological, immunological or metabolic action as a medicine; the MHRA’s guidance cites a 1991 European court ruling on minoxidil sold as a cosmetic.
AustraliaThe Poisons Standard lists minoxidil in Schedule 2 or 4 and finasteride in Schedule 4.

02Which hair studies used copper peptides, and what did they measure?

Every study we found that tested a copper peptide, or GHK, on hair or hair follicles, except one family of clinic formulations described below the table. We report design and measures, not the authors’ conclusions.

StudyModel and designWhat it testedWhat was measured
Trachy et al., 1991C3H mice; a one-page conference report co-authored by Loren Pickart, who isolated GHK from human plasma in 1973“Peptide copper complexes”Known to us only by its title
Uno and Kurata, 1993Fuzzy rats, back skin, within a review of the authors’ animal workA copper-binding peptide coded PC1031 (sequence not given in the abstract), alongside topical minoxidilHair follicle size
Pyo et al., 2007Human hair follicles kept alive outside the body, and cultured dermal papilla cellsAHK-Cu, a copper tripeptide with alanine in place of glycineFollicle elongation, cell growth, markers of cell death
Lee et al., 2016Randomised, double-blind, placebo-controlled, 6 months; 45 men with male pattern hair lossGHK chemically joined to 5-aminolevulinic acid, without copperHair count, length and thickness; satisfaction; adverse events
Bertin et al., 2018Four case reports, no control groupLaser treatment followed by topical finasteride, growth factors and a copper peptidePhotographs
Patel et al., 2024Open-label, single group, 15 days; 32 adults with dandruff enrolled, 29 completed; one author employed by the manufacturerA scalp scrub and a serum with copper tripeptide-1, witch hazel, hesperidin, hyaluronic acid and pea proteinFlaking, scalp hydration, hair density and thickness by imaging
Kuceki et al., 2025Retrospective review of 7 men with pattern hair loss; photographs rated blindA clinic procedure combining minoxidil, dutasteride and copper peptides, with topical minoxidil continuedScalp coverage, rated by four dermatologists and an AI tool
Bo et al., 2026Randomised, double-blind, split-face: one eyebrow with a GHK-Cu serum, the other with a placebo serum; 12 weeks; 18 healthy adults aged 18 to 40; conference proceedingsGHK-Cu serumEyebrow hair count and diameter, photo scores, satisfaction, adverse effects

Not in the table: QR678, a clinic-administered formulation whose published composition lists copper tripeptide-1 alongside several growth factors and other peptides. Authors from one clinic group in Mumbai have reported studies of it in hair loss since 2018, including a single-arm study of 1,000 patients; later studies compared it, or a variant whose copper content is not stated, with other treatments. With that many active ingredients, these studies cannot show anything about a copper peptide on its own.

Only the 2026 eyebrow study compares a GHK-Cu serum with a placebo, and it was in the eyebrows of healthy adults, not in scalp hair loss. Every other human study combined a copper peptide with other active ingredients or drugs, used GHK without copper, or had no control group. The animal and lab work used two other peptides, PC1031 and AHK-Cu, or is known only by its title.

03What do independent reviews say about copper peptides and hair?

Two 2026 reviews reach the question from different sides.

An evidence map of GHK-Cu. Mateescu and colleagues, in Pharmaceutics, found that its clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”, a standard the authors define around characterising the exact chemical form that was tested. They describe the eyebrow study as “a small single-center study with a cosmetic endpoint and chemically undercharacterized test material”.

A systematic review of peptides for hair loss. Joerg and colleagues, in the Journal of Drugs in Dermatology, included 14 clinical trials of peptide-containing treatments, searching to November 2025. Its abstract does not say whether any included trial used GHK bound to copper or tested a copper peptide on its own, and we could not read the full text.

We found no large trial of GHK-Cu on its own for scalp hair loss for either review to rest on. How we grade evidence: evidence grades.

04Is a copper-peptide hair product a cosmetic or a drug?

United States. FDA decides whether a product is a cosmetic or a drug by its intended use, and claims count. Among its examples of claims that make a product a drug “even if the product is marketed as if it were a cosmetic”, FDA lists claims that products “will restore hair growth”. A 1989 federal rule goes further for products sold without a prescription: any product “labeled, represented, or promoted for external use as a hair grower or for hair loss prevention” is regarded as a new drug that needs an approved application (21 CFR 310.527). The same rule records “a lack of adequate data to establish general recognition of the safety and effectiveness” of any ingredient for that use.

The medicines FDA has approved for pattern hair loss include topical minoxidil, first approved in 1988 and now sold over the counter with the label purpose “Hair regrowth treatment”, and finasteride (Propecia), a prescription tablet approved in 1997 and indicated for male pattern hair loss “in MEN ONLY”. No medicine containing GHK-Cu appears in Drugs@FDA.

United Kingdom. UK law defines a cosmetic by its purpose on the outside of the body, including the hair, and the MHRA applies medicines tests to borderline products. Its guidance note on what counts as a medicine summarises a 1991 ruling of the European Court of Justice on minoxidil sold as a cosmetic (Upjohn v Farzoo, C-112/89): male pattern baldness was not a disease, but a product is still a medicine if it is administered “with a view to ... restoring, correcting or modifying physiological functions”.

Australia. The Poisons Standard October 2026 lists minoxidil in Schedule 2 (pharmacy medicine) for skin preparations up to a set strength and in Schedule 4 (prescription only) otherwise, and finasteride in Schedule 4. We have not verified how Australian rules treat a cosmetic containing GHK-Cu.

05What we don’t know about copper peptides and hair

  • Whether GHK-Cu on its own changes scalp hair in people with hair loss. We found no published controlled trial of it alone, and no registered copper-peptide hair study on ClinicalTrials.gov (PubMed and ClinicalTrials.gov, 18 Nov 2026).
  • What the early animal work tested. The 1991 report is known to us only by its title, and the 1993 abstract does not give PC1031’s sequence.
  • How much intact GHK-Cu reaches a hair follicle from a product. None of the human hair studies above reports measuring it.
  • Long-term effects. The two placebo-controlled studies in the table ran for 12 weeks (eyebrows, 18 people) and 6 months (scalp, 45 men, GHK without copper).
  • Anything about injected GHK-Cu on its own, a different route with no controlled human data that we found: see topical GHK-Cu.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?). Web page, content current as of 11 Sep 2024; read 18 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic…
  2. 21 CFR 310.527: Drug products containing active ingredients offered over-the-counter (OTC) for external use as hair growers or for hair loss prevention (54 FR 28777, 7 Jul 1989). eCFR, text current to 16 Nov 2026; read 18 Nov 2026. www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-31…
  3. Women’s Rogaine (minoxidil topical solution), drug facts label; Drugs@FDA NDA 019501, original approval 17 Aug 1988, over-the-counter. DailyMed label, effective 6 Sep 2024; read via openFDA 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf0000c-95…
  4. Propecia (finasteride) tablets, prescribing information; Drugs@FDA NDA 020788, original approval 19 Dec 1997, prescription. DailyMed label, effective 14 Oct 2024; read via openFDA 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65…
  5. Medicines and Healthcare products Regulatory Agency. Guidance Note 8: A guide to what is a medicinal product (cosmetics; Upjohn v Farzoo, C-112/89). Guidance, linked from the MHRA borderline-products guidance updated 2 Jul 2026; PDF dated 6 Aug 2026; read 18 Nov 2026. assets.publishing.service.gov.uk/media/6a747082bde92a23046b2…
  6. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327), Schedules 2 and 4. Federal Register of Legislation, commenced 1 Oct 2026; read 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  7. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics, 2026;18(9):1077. PMID 42797253 (full text read 18 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC13610439/
  8. Joerg L, Zafar K, Jagdeo J. [Systematic review of clinical trials of peptide-containing formulations and hair]. J Drugs Dermatol, 2026;25(11):1026–1032. PMID 42976838 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/42976838/
  9. Studies of copper peptides or GHK and hair indexed in PubMed: Trachy 1991 (PMID 1809108, title only), Uno and Kurata 1993 (PMID 8326148), Pyo 2007 (PMID 17703734), Lee 2016 (PMID 27489425, full text read), Bertin 2018 (PMID 29452017), Patel 2024 (PMID 39449909, full text read), Kuceki 2025 (PMID 40225275, full text read); QR678 composition and studies: Kapoor and Shome 2018 (PMID 29482481), Kapoor et al. 2020 (PMIDs 32983753 and 32333510). Records read 18 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=1809108+OR+8326148+OR+17703734…
  10. Bo SL, Nararatwanchai T, Supornpun N, Poomarapan K, Thaploka S. [Randomised, double-blind, split-face study of a GHK-Cu serum on the eyebrows of 18 healthy adults; poster presentation]. Procedia of Multidisciplinary Research, 2026;4(5); published 22 May 2026; abstract page read 18 Nov 2026. so09.tci-thaijo.org/index.php/PMR/article/view/9318
  11. ClinicalTrials.gov. Intervention searches for “GHK-Cu”, “GHK”, “copper peptide”, “copper tripeptide”, “prezatide” and “AHK-Cu”, and condition searches for alopecia, hair loss and hypotrichosis with copper, GHK and peptide terms: no study of a copper peptide for hair. Registry searches, 18 Nov 2026. clinicaltrials.gov/search?intr=GHK-Cu
  12. PubChem. Prezatide copper, CID 71587328: synonyms include copper tripeptide-1 and GHK copper. Compound record, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/71587328

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Has GHK-Cu been tested on scalp hair loss?

Not on its own in any controlled trial we found, published or on ClinicalTrials.gov (18 Nov 2026). The one placebo-controlled study of a GHK-Cu serum we found was in the eyebrows of 18 healthy adults; other studies tested formulations in which a copper peptide was one of several active ingredients.

Is GHK-Cu an approved medicine in the US?

No. No medicine containing it appears in Drugs@FDA. The medicines FDA has approved for pattern hair loss include topical minoxidil and prescription finasteride.

Can a shampoo or serum with copper peptides claim to regrow hair?

Not as a cosmetic in the US. FDA gives a claim that a product will restore hair growth as an example of a drug claim, and a 1989 rule requires an approved application for any non-prescription hair grower.

Is copper tripeptide-1 the same as GHK-Cu?

Yes. Copper tripeptide-1 is the cosmetic name for the copper complex of glycyl-histidyl-lysine. AHK-Cu, used in some hair research, is a different copper peptide.

Is GHK the same as GHK-Cu?

No. GHK is the three-amino-acid peptide on its own; GHK-Cu is GHK bound to copper. A 2016 hair trial used GHK joined to another molecule, without copper.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page